Telegram RegisterThe public register of Telegram

Channel

[신한 리서치본부] 제약/바이오

@bio_shinhan

On this record: Topic · Observations · Also posting the same content · Growth · Engagement · What this channel posts · Posts · Citations · Cite this entry

21,246subscribers

+4 since we began measuring on 6 August 2026

Risers and fallers across the register · movement among entries of 10,000–31,623.

Register entry

Telegram ID-1001604473784
TypeChannel
Username@bio_shinhan
Description안녕하세요. 신한투자증권 제약/바이오 담당 엄민용 연구위원, 이호철 수석연구원, 윤석현 연구원(RA), 임재현 연구원(RA) 입니다. 리서치본부 내 공표된 조사분석자료를 실시간으로 제공 할 수 있도록 정보 전달을 위해 운영되는 채널입니다.
CreatedBetween 1 December 2021 and 31 March 2023— estimated from Telegram’s id allocation, not measured. How this range is calculated.
First recorded6 August 2026
Last confirmed live12 August 2026
Measurements held6
Confirmed unchanged3 times, most recently 12 August 2026
On Telegramt.me/bio_shinhan

Topic

Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-UD-Q6_K_XL, prompt version 1) read this channel’s own recent posts on 10 August 2026 and assigned it the closest of 31 fixed categories, at 66% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.

Observations

These are measurements, not verdicts. Each one below states something we counted, alongside the evidence it was counted from, so you can check it rather than take it. None of them is graded: every observation this register holds is recorded at severity 0, because the precision of the detectors behind them has not been measured yet, and a rating we cannot support is worse than none. Read each as a fact about the data, not as a judgement about the channel. How we measure.

Content that also appears on other registered channels

Posts published here appear word for word on 2 other registered channels. The matching is on the text itself, not on Telegram’s forward marker, so it finds a copy whether or not it was labelled as one.

Matching posts — open both and compare (4 of the pairs behind the counts below)
Posted firstThenOverlapGap
@bio_shinhan/4664 · this entry4 Aug 2026, 11:01 UTC@SmartnGrowth/5744 Aug 2026, 11:02 UTC1.0072 seconds
@SmartnGrowth/5794 Aug 2026, 22:55 UTC@bio_shinhan/4668 · this entry4 Aug 2026, 23:46 UTC1.0050 minutes
@alteogenIR/25130 Jul 2026, 23:08 UTC@bio_shinhan/4655 · this entry30 Jul 2026, 23:31 UTC1.0023 minutes
@alteogenIR/25431 Jul 2026, 05:31 UTC@bio_shinhan/4657 · this entry2 Aug 2026, 22:49 UTC1.003 days
Every channel this entry shares post bodies with
ChannelMatching postsText overlapTypical gapPublished first
@SmartnGrowth6 (6/6 hand-verifiable sample passed)1.003 minuteseven
@alteogenIR6 (6/6 hand-verifiable sample passed)1.0037 minutes@alteogenIR (51)

Text overlap is the Jaccard coefficient over the set of distinct three-word phrases in the two bodies: 1.00 is identical wording, and the threshold for counting a pair at all is 0.70. Candidates are generated by simhash LSH (4 x 16-bit bands, exact Hamming <= 3) verified against the bodies with Jaccard over the SET of distinct 3-word shingles. Published first counts which side of each matching pair carries the earlier timestamp — in this corpus, which is the limitation directly below.

What this cannot establish

MEASURED, DOMINANT ERROR SOURCE: a post ingested before 2026-08-06 may have carried a forward header that was not recorded. A 45-pair hand-check against live t.me pages found 14 (31%) where the live page shows a forward header naming the other channel and the database has none, plus 4 more (9%) naming a third party. The text match itself was wrong 0 times out of 45. Read attribution_capture.items_in_trusted_window before treating the unattributed count as a claim.

Telegram lets a channel forward a post with a header naming the source, and we only began reliably recording that header on 2026-08-06. None of the 2 matches recorded here fall after that date, so for this entry we cannot say whether any of them carried a credit. The duplication is measured; the absence of attribution is not.

“Published first” means first in this corpus. We hold 21 comparable posts for this entry, running 30 July 2026 to 7 August 2026. A channel we have read one page deep will look younger than a neighbour we have read in full, and the order would flip with no change in the underlying facts.

The detector’s own notes on this observation, as it recorded them. Names in this_style are fields of the underlying evidence record, which the plain-English paragraphs above read out for this entry.

  • Verbatim republication has three causes and the text separates only two: a clone/mirror, unattributed copy-paste, or BOTH channels copying a common third source that neither attributes. The spread filter (content held by at most 8 channels) reduces the third and does not remove it.
  • 'Earliest' means earliest IN THIS CORPUS. A channel ingested one page deep will look younger than a neighbour ingested in full; corpus_coverage above is there to be checked before the direction is believed.
  • shared_verified_est extrapolates the sampled pass rate over the full narrow match count; sampled/passed are the numbers actually measured.
  • Absence of a forward header is not proof of intent: Telegram lets a channel disable forward attribution, and a credit written in the body is not parsed as attribution here (mention_edge_either_way above is the closest available signal).

Across the whole group of 3, the earliest publisher we hold is @alteogenIR. That is a statement about our reading window, not a claim of authorship.

Recorded under the keys clone_copy · clone_mutual, last confirmed 7 August 2026. An observation that a later pass no longer finds is cleared, and a cleared observation is removed from this page rather than being shown struck through — we do not keep publishing a claim we have withdrawn. Dispute an observation.

Also posting the same content

This channel’s posts match, word for word or near enough, posts on 2 other registered channels, found by comparing text fingerprints across every channel on the register. That matching has been checked by hand against the live Telegram pages and found reliable — 0 wrong of 45 pairs re-read.

Which channel, if either, published first is deliberately not shown. The same hand-check found that reading wrong 18 of 45 times — 60%, no better than a coin flip — because it depends on how deep our own crawl happened to reach into each channel’s history, not on when the content was actually first posted. This list is ordered by subscriber count, the same as every other listing on this site, never by which channel we think came first. Word-for-word matching has several ordinary explanations besides copying — a channel mirroring itself, an unattributed repost, or two channels independently repeating the same wire story — and this measurement cannot tell those apart. How this is measured.

Growth

21,23521,24621,240.56 August 2026 — 21,242 subscribers6 August 2026 — 21,241 subscribers7 August 2026 — 21,236 subscribers8 August 2026 — 21,235 subscribers9 August 2026 — 21,237 subscribers10 August 2026 — 21,246 subscribers6 August 202610 August 2026
6 measurements spanning 5 days, net +4. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 21,233–21,248 and does not start at zero.
Measurement log — every subscribers count we have recorded
Measured (UTC)SubscribersChange
10 Aug 2026, 17:2821,246+9
9 Aug 2026, 15:1221,237+2
8 Aug 2026, 12:3621,235-1
7 Aug 2026, 13:1321,236-5
6 Aug 2026, 12:2121,241-1
6 Aug 2026, 04:4721,242first reading

Engagement

38 posts held, back to 30 July 2026the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 17 pagesof Telegram’s post history, 20 posts per page.

ERR · 30 days
29.0%
avg views ÷ 21,246 subscribers
Avg views / post
6,170
38 posts measured
Reaction rate
this channel exposes no reaction counts
Posts in window
38
of 38 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.

What these figures were computed from
WindowRolling 30 days · latest post in window 12 August 2026
Posts held38 (30 July 202612 August 2026)
Views total234,521
Reactions total
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken12 Aug 2026, 23:13 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

What this channel posts

Photos
802
Links
3,250

Lifetime counters from Telegram’s own channel header, read 12 August 2026 — not the date at the top of this page, which is when the subscriber count was last read. A count marked was rounded by Telegram before we ever saw it — t.me prints these counters in full below 1,000 and to three significant figures above, so ≈142,000 means somewhere between 141,500 and 142,499.

Recent posts

12 Aug 2026, 23:12 UTC601 viewsread 12 August 2026

『에보뮨 (EVMN.US) - EVO-dyssey: 아토피를 향한 항해』 기업분석부 이호철, 엄민용 ☎️ 02-3772-2669 ▶️ 신한생각: EVO301이 그리는 다음 항로, 아토피 릴리에서 스핀오프한 뉴코. 블록버스터 아토피 치료제 엡글리스(32년 매출 29억달러 예상) 개발한 루이스 페냐가 창립. 2개 신약 임상 결과 주목 필요. ① EVO756(경구 MRGPRX2 억제제, 릴리 L/I), ② EVO301(IL-18 억제제, 에이프릴바이오 L/I) 모두 올해 9월 아토피 2상 데이터 발표 예정 ▶️ 블록버스터 개발 & 릴리 엑싯 경험자가 창립한 뉴코 20년 4월 설립된 뉴코로 주요 주주는 전문 바이오 VC 및 헬스케어 펀드. CEO 루이스 페냐는 더미라(엡글리스 원개발사) 공동 창업자. 20년 2월 더미라가 릴리에 11억달러 규모로

12 Aug 2026, 22:54 UTC≈3,070 viewsread 12 August 2026

[머크/알테오젠 SC 후속 특허 기사 코멘트] 머크/켈룬 EGFR·c-MET, ALPP·ALPPL2, TROP2 등 단일 또는 이중항체 ADC 계열 특허 청구항에 알테오젠 ALT-B4를 명시 머크와 최소 6개 물질 SC 개발 가능한데 키트루다SC 이후 개발 품목을 예상 가능한 특허가 공개, 대부분 ADC SC에 집중 가장 처음 다이이찌 산쿄가 알테오젠과 엔허투SC 계약 후 GSK가 할로자임과 ADC SC를 경쟁적으로 계약했고, 기존 파트너사인 머크도 ADC SC 개발이 본격화될 것 이제 곧 나머지 ADC 개발사들 화이자/시젠, 길리어드, 론자/이노벤트, 베링거 인겔하임, J&J 등 선두 그룹들의 ADC SC 개발 경쟁 양상 나올 것 [단독]알테오젠 ALT-B4, 키트루다 외 적용 확대되나…머크·켈룬 단일/이중항체 ADC SC 특허서 포

12 Aug 2026, 22:49 UTC≈1,610 viewsread 12 August 2026

✅ 2026.08.13(목) 바이오/제약 주요 뉴스 알테오젠 ALT-B4, 키트루다 외 적용 확대되나…머크·켈룬 특허서 포착, 켈룬 EGFR·c-MET 계열과 머크 ALPP·ALPPL2 계열 특허 청구항에 ALT-B4 명시 https://www.markettimes.co.kr/2026/08/12/%ec%95%8c%ed%85%8c%ec%98%a4%ec%a0%a0-alt-b4-%ed%82%a4%ed%8a%b8%eb%a3%a8%eb%8b%a4-%ec%99%b8-%ec%a0%81%ec%9a%a9-%ed%99%95%eb%8c%80%eb%90%98%eb%82%98%eb%a8%b8%ed%81%ac%ec%bc%88%eb%a3%ac-%ed%8a%b9/ 아케소/서밋의 면역항암제 신약 이보네시맙(PD-1 x VEGF 이중항체), 중국 편평 비소세포폐암(sq-N

12 Aug 2026, 22:08 UTC≈5,380 viewsread 12 August 2026
Photo

한올바이오파마 파트너사 이뮤노반트 +4.08% 상승해 52주 신고가 경신, 시가총액 12.5조원

12 Aug 2026, 06:19 UTC≈2,480 viewsread 12 August 2026
Forwarded from @olix_official

안녕하세요, 올릭스 커뮤니케이션실입니다. 금일 주가 변동으로 인해 많이 걱정하고 계실 주주 여러분의 마음을 잘 알고 있습니다. 특히 지난해 발행한 CPS의 보통주 전환 가능 시점이 다가오면서, 관련 물량이 단기간에 시장에 출회되는 것 아니냐는 우려가 있으신 것으로 파악하고 있습니다. 이에 현재 상황을 주주 여러분께 직접 설명드리고자 합니다. ■ CPS 전환 가능 시점 관련 해당 CPS의 보통주 전환청구 가능 개시일은 8월 29일이나, 해당일이 토요일인 관계로 실제 전환청구가 가능한 첫 영업일은 8월 31일입니다. 전환청구가 이루어진다고 하더라도 실제 보통주가 상장되어 거래 가능해지기까지는 일정 기간이 소요됩니다. 따라서 전환 가능 물량 전체가 8월 31일부터 즉시 시장에 출회되는 구조는 아닙니다. ■ 기존 CPS 투자자 관련 당시 투자

12 Aug 2026, 01:04 UTC≈4,570 viewsread 12 August 2026
Forwarded from @thebio111

리보핵산(RNA) 간섭 기술 기반의 혁신신약 개발기업인 올릭스는 피하주사(SC) 또는 정맥주사(IV)로 투여한 작은 간섭 RNA(siRNA) 물질이 뇌의 깊은 부위를 포함한 다양한 뇌 영역에서 표적 유전자를 억제하는 것을 확인했다고 밝혔습니다. 올릭스의 원천 플랫폼인 ‘OASIS(OliX Advanced Small Interfering RNA System)-CNS’를 기반으로 기존에 확보한 CNS 표적 siRNA를 전신 투여형 물질로 확장한 결과로, 회사의 CNS 신약 개발이 플랫폼 구축을 넘어 실제 질환 치료제 개발 단계로 진전되고 있음을 보여줍니다. 올릭스는 siRNA에 뇌혈관장벽(BBB)을 통과할 수 있는 셔틀을 결합한 2세대 OASIS-CNS 플랫폼을 개발하고 있습니다. 이번 연구에서는 해당 물질을 생쥐에 피하 또는 정맥 투여한 결

11 Aug 2026, 22:58 UTC≈4,250 viewsread 12 August 2026

✅ 2026.08.12(수) 바이오/제약 주요 뉴스 한올바이오파마, 자체 진행하던 바토클리맙(1401) 갑상선안병증 일본 임상 종료로 2분기 경상연구개발비 감소…하반기 아이메로프루바트(1402) 류마티스 등록임상 탑라인과 루푸스 임상 탑라인 발표 등 이벤트 다수 주목 https://www.hitnews.co.kr/news/articleView.html?idxno=78331 중국 아케소, AK146D1(TROP2 x 넥틴4 이중항체 ADC) + 이보네시맙(VEGF x PD-1 이중항체) 유방암 2상 첫 투여: 200명 등록 목표, 오는 2029년 2월 임상 종료 예정...차세대 항암 전략 ‘IO 2.0+ADC 2.0’ 일환 https://www.thebionews.net/news/articleView.html?idxno=27098 AC Im

10 Aug 2026, 22:48 UTC≈5,010 viewsread 12 August 2026

✅ 2026.08.11(화) 바이오/제약 주요 뉴스 ‘키트루다SC’ 첫 외부 병용 임상 개시하며 키트루다SC 중심의 병용요법 전개 시사…엑셀리시스의 '잔잘린티닙’ MRD(분자잔존질환) 양성 대장암 3상 병용, 외부 제약사 주도 병용 확장 시 알테오젠 수익 기반 확대 의의 https://www.thebionews.net/news/articleView.html?idxno=27080 미래에셋자산운용, 지난 3일 올릭스 6.19만주 추가 매수로 지분율 5.14%(+0.29%p) 확보…단순 투자 목적으로 공시 https://www.thebionews.net/news/articleView.html?idxno=27075 블랙록, 유한양행 주식 74.5만주 추가 매입…지분율 5.07%에서 6.5%로 1.43%p 확대, 단순 투자 목적으로 공시 https

10 Aug 2026, 22:26 UTC≈5,850 viewsread 12 August 2026

* 요약: 이제 MSD와 키트루다 병용 약물 협력을 맺으면 IV가 아닌 키트루다SC를 준다 (이제 파트너사도 병용요법 상업화하려면 SC로 받아라)

10 Aug 2026, 22:22 UTC≈4,430 viewsread 12 August 2026
Forwarded from @thebio111

알테오젠의 피하주사(SC) 제형 변경 기술(인간 히알루로니다제, ALT-B4)이 적용된 ‘키트루다SC(미국명 키트루다 큐렉스)’가 처음으로 다국적 제약사 MSD(미국 머크)가 아닌 외부 제약사 주도의 병용 임상을 시작합니다. 미국 바이오기업인 엑셀리시스(Exelixis)는 MSD와 임상 개발 협력을 맺고, 대장암 임상3상에서 자체 신약 후보물질인 ‘잔잘린티닙(zanzalintinib)’과 키트루다SC 병용요법 평가를 예고했습니다. 이번 병용 임상은 MSD가 외부 제약사 주도 병용 임상에 키트루다SC를 공급하는 첫 사례로, 그동안 정맥주사(IV) 중심으로 확장해온 키트루다의 생태계가 SC 제형으로 진전하고 있는 것이어서 주목됩니다. 미국 임상시험정보사이트인 클리니컬트라이얼스에 따르면, 엑셀리시스는 분자잔존질환(MRD)이 확인된 2·3기 대장암

10 Aug 2026, 11:04 UTC≈10,100 viewsread 12 August 2026
Photo

한올바이오파마 파트너사 이뮤노반트 52주 신고가 수준 2개월째 강하게 유지 중. 신고가 $41.57 터치

10 Aug 2026, 08:40 UTC≈3,580 viewsread 12 August 2026
Forwarded from @darthacking

2026.08.10 16:38:11 기업명: 유한양행(시가총액: 6조 5,311억) A000100 보고서명: 주식등의대량보유상황보고서(약식) 대표보고 : 블랙록 펀드 어드바이저스/미국 보유목적 : 단순투자 보고전 : 5.07% 보고후 : 6.50% 보고사유 : - 단순투자목적으로 장내에서 발행회사의 주식 매수 * BlackRock (Singapore) Limited 2026-07-13/장내매수(+)/보통주/ 28주/- 2026-07-22/장내매수(+)/보통주/ 260주/- * BlackRock Advisors (UK) Limited 2026-07-27/장내매수(+)/보통주/ 455주/- 2026-07-28/장내매수(+)/보통주/ 455주/- 2026-07-29/장내매수(+)/보통주/ 8주/- 2026-07-30/장내매수(+)/보통주/

Showing the 12 most recent of 38 posts we hold for @bio_shinhan. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Citation-graph rank

Citation-graph rank — 83,580 of 1,151,006entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.

Forward network

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Named by 3 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.

Names

Channels on the register whose handles appear in this channel's posts.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 10 August 2026 — this entry's latest reading, not the date you are reading this.

“[신한 리서치본부] 제약/바이오” (@bio_shinhan), 21,246 subscribers as measured 10 August 2026. Telegram Register, tgregister.com/channel/bio_shinhan.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.